BWS Financial Downgrades SciClone Pharmaceuticals (SCLN) to Hold; SEC Investigation Overhang
SCLN Hot Sheet
Rating Summary:1 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 22
BWS Financial downgrades SciClone Pharmaceuticals (Nasdaq: SCLN) from Buy to Hold.
BWS analyst says, "What was a positive earnings report from SciClone was quickly overshadowed by a formal SEC investigation into the Company...We fear that the investigation could drag out for months and cost the Company millions in legal fees. The SEC has launched a series of FCPA investigations in the past year leading to some settlements. There is no assurance if the SEC would find anything in their investigation, but since this is a formal inquiry we are hesitant to recommend buying the stock. The fundamentals remain solid and the Company should be able to continue to generate revenue. However, such an investigation could result in management changes and other distractions that could slow the sales momentum SCLN is currently experiencing."
To see all the upgrades/downgrades on shares of SCLN, visit our Analyst Ratings page.
SciClone Pharmaceuticals, Inc. (SciClone ) is a global specialty pharmaceutical company.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
BWS analyst says, "What was a positive earnings report from SciClone was quickly overshadowed by a formal SEC investigation into the Company...We fear that the investigation could drag out for months and cost the Company millions in legal fees. The SEC has launched a series of FCPA investigations in the past year leading to some settlements. There is no assurance if the SEC would find anything in their investigation, but since this is a formal inquiry we are hesitant to recommend buying the stock. The fundamentals remain solid and the Company should be able to continue to generate revenue. However, such an investigation could result in management changes and other distractions that could slow the sales momentum SCLN is currently experiencing."
To see all the upgrades/downgrades on shares of SCLN, visit our Analyst Ratings page.
SciClone Pharmaceuticals, Inc. (SciClone ) is a global specialty pharmaceutical company.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Goldman Sachs Downgrades Raytheon (RTN) to Sell; Risk To Back-End Loaded 2012
- UBS Maintains a 'Buy' on Teva Pharma (TEVA); CEO Highlights From Conference Call
Create E-mail Alert Related Categories
DowngradesRelated Entities
BWS FinancialSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
